title: Involvement of Elk-1 in L6E9 skeletal muscle differentiation.
abstract: In L6E9 skeletal muscle cells ternary complex factor (TCF) Elk-1 expression increased with the onset of skeletal muscle differentiation, whereas its activation decreased as a function of differentiation. Its expression was predominantly restricted to cytoplasm and activated ones were predominantly restricted to the nucleus of the differentiated cells. Inhibition of ERK-1/-2 activities by PD098059 resulted into significant reduction in Elk-1 expression and phosphorylation during differentiation. In contrast, inhibition of p38 mitogen-activated protein kinase (MAPK) enhanced Elk-1 expression and activation, thereby mediating inhibition of skeletal muscle differentiation. Overexpression of inactive mutant Elk-1 enhanced differentiation. Data suggest that ERK-1/-2 and p38 MAPK activities modulate Elk-1 expression and activation to regulate skeletal muscle differentiation.
authors.affiliation: Signal Transduction Research Laboratory, Department of Biotechnology, National Institute of Pharmaceutical Education and Research, 160 062, Punjab, India.
authors.forename: Ashwani
authors.initials: A
authors.lastname: Khurana
authors.forename: Chinmoy S
authors.initials: CS
authors.lastname: Dey
mesh_terms: D000818:Animals; D002454:Cell Differentiation / Q000187:drug effects / Q000502:physiology; D002467:Cell Nucleus / Q000187:drug effects / Q000378:metabolism; D002478:Cells, Cultured; D003593:Cytoplasm / Q000187:drug effects / Q000378:metabolism; D004268:DNA-Binding Proteins; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005419:Flavonoids / Q000494:pharmacology; D007093:Imidazoles / Q000494:pharmacology; D019950:Mitogen-Activated Protein Kinase 1 / Q000037:antagonists & inhibitors / Q000378:metabolism; D048052:Mitogen-Activated Protein Kinase 3; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D018482:Muscle, Skeletal / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism*; D009154:Mutation; D010766:Phosphorylation; D011518:Proto-Oncogene Proteins / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D011725:Pyridines / Q000494:pharmacology; D051381:Rats; D014157:Transcription Factors; D050807:ets-Domain Protein Elk-1; D048051:p38 Mitogen-Activated Protein Kinases
chemical_list: D004268:DNA-Binding Proteins; C494114:Elk1 protein, rat; D004791:Enzyme Inhibitors; D005419:Flavonoids; D007093:Imidazoles; D011518:Proto-Oncogene Proteins; D011725:Pyridines; D014157:Transcription Factors; D050807:ets-Domain Protein Elk-1; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; D020928:Mitogen-Activated Protein Kinases; D048051:p38 Mitogen-Activated Protein Kinases; C093642:SB 203580; C093973:2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one